Botulinum Injections for Idiopathic Cervical Dystonia: a Longitudinal Study

[1]  B. Leplow,et al.  Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle , 2020, Brain and behavior.

[2]  H. Hefter,et al.  Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy , 2020, Frontiers in Neurology.

[3]  A. Pisani,et al.  Demographic and clinical determinants of neck pain in idiopathic cervical dystonia , 2020, Journal of Neural Transmission.

[4]  M. Tijssen,et al.  Prevalence of non‐motor symptoms and their association with quality of life in cervical dystonia , 2020, Acta neurologica Scandinavica.

[5]  P. Hluštík,et al.  The Prevalence of Dystonic Tremor and Tremor Associated with Dystonia in Patients with Cervical Dystonia , 2018, Scientific Reports.

[6]  Sara C. LaHue,et al.  Cervical Dystonia Incidence and Diagnostic Delay in a Multiethnic Population , 2019, Movement disorders : official journal of the Movement Disorder Society.

[7]  Massimiliano Valeriani,et al.  Pain in cervical dystonia: Evidence of abnormal inhibitory control. , 2019, Parkinsonism & related disorders.

[8]  E. Pekkonen,et al.  Comorbidity and retirement in cervical dystonia , 2019, Journal of Neurology.

[9]  B. Haslinger,et al.  Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice , 2019, Journal of Neurology.

[10]  B. Haslinger,et al.  Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study , 2019, Journal of the Neurological Sciences.

[11]  A. Schrammb,et al.  Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput_ Results from a German-Austrian open-label prospective post-marketing surveillance study , 2019 .

[12]  A. Bentivoglio,et al.  Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia , 2017, Neurotoxicity Research.

[13]  M. Hallett,et al.  Clinical and demographic characteristics related to onset site and spread of cervical dystonia , 2016, Movement disorders : official journal of the Movement Disorder Society.

[14]  S. Tomic,et al.  Cervical dystonia and quality of life , 2016, Acta Neurologica Belgica.

[15]  Michael K. Hutchinson,et al.  Age-Related Sexual Dimorphism in Temporal Discrimination and in Adult-Onset Dystonia Suggests GABAergic Mechanisms , 2015, Front. Neurol..

[16]  J. Finsterer,et al.  Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift , 2015, Journal of the Neurological Sciences.

[17]  V. P. Misra,et al.  Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study , 2012, BMJ Open.

[18]  J. Jankovic,et al.  Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. , 2010, Parkinsonism & related disorders.

[19]  A. Felício,et al.  Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia , 2009, Neurological Sciences.

[20]  A. Stenner,et al.  [The phenomenology of cervical dystonia]. , 2009, Fortschritte der Neurologie-Psychiatrie.

[21]  J. Jankovic,et al.  Long‐term botulinum toxin efficacy, safety, and immunogenicity , 2005, Movement disorders : official journal of the Movement Disorder Society.

[22]  E. Elovic,et al.  Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke , 2004, Neurology.

[23]  D. Dressler.  Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy , 2004, Movement disorders : official journal of the Movement Disorder Society.

[24]  R. Benecke,et al.  Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. , 1999, Journal of neurology.

[25]  L. Simpson.  The origin, structure, and pharmacological activity of botulinum toxin. , 1981, Pharmacological reviews.